{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:31:16Z","timestamp":1762079476092,"version":"3.41.2"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1212\/01.con.0000464180.89580.88","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T12:05:26Z","timestamp":1428062726000},"page":"452-475","source":"Crossref","is-referenced-by-count":19,"title":["Paraneoplastic Disorders"],"prefix":"10.1212","volume":"21","author":[{"given":"Eric","family":"Lancaster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Marx A Pfister F Schalke B et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013; 12 (9): 875\u2013884. doi:10.1016\/j.autrev.2013.03.007.","DOI":"10.1016\/j.autrev.2013.03.007"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Vernino S Lennon VA. Neuronal ganglionic acetylcholine receptor autoimmunity. Ann N Y Acad Sci 2003; 998: 211\u2013214. doi:10.1196\/annals.1254.023.","DOI":"10.1196\/annals.1254.023"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Titulaer MJ Lang B Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10 (12): 1098\u20131107. doi:10.1016\/S1474-4422(11)70245-9.","DOI":"10.1016\/S1474-4422(11)70245-9"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","unstructured":"Burk K Wick M Roth G et al. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010; 257 (1): 59\u201362. doi:10.1007\/s00415-009-5262-8.","DOI":"10.1007\/s00415-009-5262-8"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"European Federation of Neurological Societies; Peripheral Nerve Society Hadden RD Nobile-Orazio E Sommer C et al. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13 (8): 809\u2013818. doi:10.1111\/j.1468-1331.2006.01467.x.","DOI":"10.1111\/j.1468-1331.2006.01467.x"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","unstructured":"Arin\u02dco H Gresa-Arribas N Blanco Y et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies immunologic profile and long-term effect of immunotherapy. JAMA Neurol 2014; 71 (8): 1009\u20131016. doi:10.1001\/jamaneurol.2014.1011.","DOI":"10.1001\/jamaneurol.2014.1011"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","unstructured":"Pittock SJ Lucchinetti CF Parisi JE et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58 (1): 96\u2013107. doi:10.1002\/ana.20529.","DOI":"10.1002\/ana.20529"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Irani SR Pettingill P Kleopa KA et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 2012; 72 (2): 241\u2013255. doi:10.1002\/ana.23577.","DOI":"10.1002\/ana.23577"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Graus F Keime-Guibert F Rene R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124 (pt 6): 1138\u20131148. doi:10.1093\/brain\/124.6.1138.","DOI":"10.1093\/brain\/124.6.1138"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Hoffmann LA Jarius S Pellkofer HL et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79 (7): 767\u2013773. doi:10.1136\/jnnp.2007.118588.","DOI":"10.1136\/jnnp.2007.118588"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","unstructured":"Dalmau J Graus F Villarejo A et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127 (pt 8): 1831\u20131844. doi:10.1093\/brain\/awh203.","DOI":"10.1093\/brain\/awh203"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Peterson K Rosenblum MK Kotanides H Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42 (10): 1931\u20131937. doi:10.1212\/WNL.42.10.1931.","DOI":"10.1212\/WNL.42.10.1931"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","unstructured":"Pittock SJ Lucchinetti CF Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003; 53 (5): 580\u2013587. doi:10.1002\/ana.10518.","DOI":"10.1002\/ana.10518"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","unstructured":"Honnorat J Cartalat-Carel S Ricard D et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2\/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009; 80 (4): 412\u2013416. doi:1136\/jnnp.2007.138016.","DOI":"10.1136\/jnnp.2007.138016"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Vernino S Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000; 47 (3): 297\u2013305. doi:10.1002\/1531-8249(200003)47:3<297::AID-ANA4>3.0.CO;2-4.","DOI":"10.1002\/1531-8249(200003)47:3<297::AID-ANA4>3.0.CO;2-4"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Chan KH Vernino S Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001; 50 (3): 301\u2013311. doi:10.1002\/ana.1127.","DOI":"10.1002\/ana.1127"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Pittock SJ Yoshikawa H Ahlskog JE et al. Glutamic acid decarboxylase autoimmunity with brainstem extrapyramidal and spinal cord dysfunction. Mayo Clin Proc 2006; 81 (9): 1207\u20131214. doi:10.4065\/81.9.1207.","DOI":"10.4065\/81.9.1207"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Burton AR Baquet Z Eisenbarth GS et al. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol 2010; 184 (9): 4863\u20134870. doi:10.4049\/jimmunol.0903728.","DOI":"10.4049\/jimmunol.0903728"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Dalmau J Lancaster E Martinez-Hernandez E et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10 (1): 63\u201374. doi:10.1016\/S1474-4422(10)70253-2.","DOI":"10.1016\/S1474-4422(10)70253-2"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Moscato EH Jain A Peng X et al. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory behavior and cognition: insights from molecular cellular and synaptic studies. Eur J Neurosci 2010; 32 (2): 298\u2013309. doi:10.1111\/j.1460-9568.2010.07349.x.","DOI":"10.1111\/j.1460-9568.2010.07349.x"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Lai M Hughes EG Peng X et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65 (4): 424\u2013434. doi:10.1002\/ana.21589.","DOI":"10.1002\/ana.21589"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Gleichman AJ Panzer JA Baumann BH et al. Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis. Ann Clin Transl Neurol 2014; 1 (1): 180\u2013189. doi:10.1002\/acn3.43.","DOI":"10.1002\/acn3.43"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Irani SR Alexander S Waters P et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis Morvan\u2019s syndrome and acquired neuromyotonia. Brain 2010; 133 (9): 2734\u20132748. doi:10.1093\/brain\/awq213.","DOI":"10.1093\/brain\/awq213"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Lai M Huijbers MG Lancaster E et al. Investigation of LGI1 as the antigen in limbic previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9 (8): 776\u2013785. doi:10.1016\/S1474-4422(10)70137-X.","DOI":"10.1016\/S1474-4422(10)70137-X"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Ohkawa T Fukata Y Yamasaki M et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013; 33 (46): 18161\u201318174. doi:10.1523\/JNEUROSCI.3506-13.2013.","DOI":"10.1523\/JNEUROSCI.3506-13.2013"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","unstructured":"Hoftberger R Titulaer MJ Sabater L et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013; 81 (17): 1500\u20131506. doi:10.1212\/WNL.0b013e3182a9585f.","DOI":"10.1212\/WNL.0b013e3182a9585f"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Petit-Pedrol M Armangue T Peng X et al. Encephalitis with refractory seizures status epilepticus and antibodies to the GABAA receptor: a case series characterisation of the antigen and analysis of the effects of antibodies. Lancet Neurol 2014; 13 (3): 276\u2013286. doi:10.1016\/S1474-4422(13)70299-0.","DOI":"10.1016\/S1474-4422(13)70299-0"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"Lancaster E Martinez-Hernandez E Titulaer MJ et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011; 77 (18): 1698\u20131701. doi:10.1212\/WNL.0b013e3182364a44.","DOI":"10.1212\/WNL.0b013e3182364a44"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","unstructured":"Coesmans M Smitt PA Linden DJ et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003; 53 (3): 325\u2013336. doi:10.1002\/ana.10451.","DOI":"10.1002\/ana.10451"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Zuliani L Sabater L Saiz A et al. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology 2007; 68 (3): 239\u2013240. doi:10.1212\/01.wnl.0000251308.79366.f9.","DOI":"10.1212\/01.wnl.0000251308.79366.f9"},{"key":"e_1_3_1_33_2","doi-asserted-by":"crossref","unstructured":"Hoftberger R Sabater L Ortega A et al. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol 2013; 70 (4): 506\u2013509. doi:10.1001\/jamaneurol.2013.1955.","DOI":"10.1001\/jamaneurol.2013.1955"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"de Graaff E Maat P Hulsenboom E et al. Identification of delta\/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012; 71 (6): 815\u2013824. doi:10.1002\/ana.23550.","DOI":"10.1002\/ana.23550"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Dale RC Merheb V Pillai S et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012; 135 (pt 11): 3453\u20133468. doi:10.1093\/brain\/aws256.","DOI":"10.1093\/brain\/aws256"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Cox CJ Sharma M Leckman JF et al. Brain human monoclonal autoantibody from Sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: implications in human disease. J Immunol 2013; 191 (11): 5524\u20135541. doi:10.4049\/jimmunol.1102592.","DOI":"10.4049\/jimmunol.1102592"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Hutchinson M Waters P McHugh J et al. Progressive encephalomyelitis rigidity and myoclonus: a novel glycine receptor antibody. Neurology 2008; 71 (16): 1291\u20131292. doi:10.1212\/01.wnl.0000327606.50322.f0.","DOI":"10.1212\/01.wnl.0000327606.50322.f0"},{"key":"e_1_3_1_38_2","doi-asserted-by":"crossref","unstructured":"Clowse ME Behera MA Anders CK et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009; 18 (3): 311\u2013319. doi:10.1089\/jwh.2008.0857.","DOI":"10.1089\/jwh.2008.0857"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","unstructured":"Gresa-Arribas N Titulaer MJ Torrents A et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13 (2): 167\u2013177. doi:10.1016\/S1474-4422(13)70282-5.","DOI":"10.1016\/S1474-4422(13)70282-5"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/01.CON.0000464180.89580.88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:00:31Z","timestamp":1752156031000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/01.CON.0000464180.89580.88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1212\/01.CON.0000464180.89580.88"],"URL":"https:\/\/doi.org\/10.1212\/01.con.0000464180.89580.88","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"type":"print","value":"1080-2371"},{"type":"electronic","value":"1538-6899"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}